Omeros Co. (OMER) Expected to Announce Quarterly Sales of $23.45 Million

Equities research analysts expect Omeros Co. (NASDAQ:OMER) to announce $23.45 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Omeros’ earnings. The lowest sales estimate is $22.50 million and the highest is $24.40 million. Omeros reported sales of $12.91 million in the same quarter last year, which would suggest a positive year over year growth rate of 81.6%. The firm is scheduled to issue its next quarterly earnings results on Thursday, March 15th.

According to Zacks, analysts expect that Omeros will report full year sales of $23.45 million for the current fiscal year, with estimates ranging from $73.57 million to $75.50 million. For the next financial year, analysts anticipate that the business will post sales of $110.76 million per share, with estimates ranging from $100.01 million to $121.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Omeros.

A number of research analysts have recently weighed in on the company. Maxim Group set a $24.00 price target on Omeros and gave the company a “buy” rating in a research note on Wednesday, January 3rd. ValuEngine raised Omeros from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright set a $30.00 price target on Omeros and gave the company a “buy” rating in a research note on Wednesday, November 29th. Zacks Investment Research downgraded Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 25th. Finally, Wedbush reissued an “outperform” rating and issued a $47.00 price target on shares of Omeros in a research note on Tuesday, November 28th. Five research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $34.14.

Omeros (OMER) opened at $14.09 on Friday. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. The firm has a market capitalization of $681.21, a price-to-earnings ratio of -10.92 and a beta of 3.30. Omeros has a 12 month low of $10.45 and a 12 month high of $27.09.

Hedge funds have recently bought and sold shares of the company. C M Bidwell & Associates Ltd. acquired a new stake in Omeros during the 4th quarter worth $106,000. First Interstate Bank acquired a new stake in Omeros during the 3rd quarter worth $108,000. Hanseatic Management Services Inc. raised its stake in Omeros by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,592 shares during the period. Malaga Cove Capital LLC acquired a new stake in Omeros during the 4th quarter worth $242,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in Omeros during the 3rd quarter worth $256,000. 50.23% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Omeros Co. (OMER) Expected to Announce Quarterly Sales of $23.45 Million” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/11/omeros-co-omer-expected-to-announce-quarterly-sales-of-23-45-million.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Get a free copy of the Zacks research report on Omeros (OMER)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply